Evidence map›Paper›PMID 35907758›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2022

Gamma-glutamyltransferase is a strong predictor of secondary sclerosing cholangitis after lung transplantation for COVID-19 ARDS.

Stefan Schwarz, Christian Lang, Matevz Harlander, Tomaz Štupnik, Jan Van Slambrouck, Laurens J Ceulemans, Fabio Ius, Jens Gottlieb, Stefan Kuhnert, Matthias Hecker and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. The role of coronary artery disease in lung transplantation: a propensity-matched analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Article
  5. Post-COVID-19 cholangiopathy: Systematic review.World journal of methodology · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Stefan SchwarzDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Christian LangDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Matevz HarlanderDepartment of Pulmonary Diseases, University Medical Center, Ljubljana, Slovenia.
Tomaz ŠtupnikDepartment of Thoracic Surgery, University Medical Center, Ljubljana, Slovenia.
Jan Van SlambrouckDepartment of Thoracic Surgery, Lab of BREATHE, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Laurens J CeulemansDepartment of Thoracic Surgery, Lab of BREATHE, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Fabio IusDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Jens GottliebDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Stefan KuhnertDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine II, University Hospital Giessen, Justus Liebig University of Giessen, Giessen, Germany.
Matthias HeckerDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine II, University Hospital Giessen, Justus Liebig University of Giessen, Giessen, Germany.
Clemens AignerDepartment of Thoracic Surgery, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, Essen, Germany.
Nikolaus KneidingerDepartment of Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of German Center for Lung Research (DZL), Munich, Germany.
Erik Am VerschuurenDepartment of Respiratory Diseases, Tuberculosis and Lung Transplantation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jacqueline M SmitsEurotransplant International Foundation, Leiden, The Netherlands.
Edda TschernkoDivision of Cardiac, Thoracic and Vascular Anesthesia and Intensive Care, Medical University of Vienna, Vienna, Austria.
Eva SchadenDepartment of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria.
Peter FaybikDepartment of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria.
Klaus MarkstallerDepartment of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria.
Michael TraunerDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Peter JakschDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Konrad HoetzeneckerDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria. Electronic address: konrad.hoetzenecker@meduniwien.ac.at.
Medical University of Vienna · ATJustus-Liebig-Universität Gießen · DEKU Leuven · BELjubljana University Medical Centre · SIMedizinische Hochschule Hannover · DEEurotransplant · NLGerman Center for Lung Research · DERuhrlandklinik · DEUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung transplantation (LTx) can be considered for selected patients suffering from COVID-19 acute respiratory distress syndrome (ARDS). Secondary sclerosing cholangitis in critically ill (SSC-CIP) patients has been described as a late complication in COVID-19 ARDS survivors, however, rates of SSC-CIP after LTx and factors predicting this detrimental sequela are unknown.

methodsThis retrospective analysis included all LTx performed for post-COVID ARDS at 8 European LTx centers between May 2020 and January 2022. Clinical risk factors for SSC-CIP were analyzed over time. Prediction of SSC-CIP was assessed by ROC-analysis.

resultsA total of 40 patients were included in the analysis. Fifteen patients (37.5%) developed SSC-CIP. GGT at the time of listing was significantly higher in patients who developed SSC-CIP (median 661 (IQR 324-871) vs 186 (109-346); p = 0.001). Moreover, higher peak values for GGT (585 vs 128.4; p < 0.001) and ALP (325 vs 160.2; p = 0.015) were found in the 'SSC' group during the waiting period. Both, GGT at the time of listing and peak GGT during the waiting time, could predict SSC-CIP with an AUC of 0.797 (95% CI: 0.647-0.947) and 0.851 (95% CI: 0.707-0.995). Survival of 'SSC' patients was severely impaired compared to 'no SSC' patients (1-year: 46.7% vs 90.2%, log-rank p = 0.004).

conclusionsSSC-CIP is a severe late complication after LTx for COVID-19 ARDS leading to significant morbidity and mortality. GGT appears to be a sensitive parameter able to predict SSC-CIP even at the time of listing.

Indexed as

Cholangitis, SclerosingCOVID-19Lung TransplantationRespiratory Distress Syndromegamma-GlutamyltransferaseHumansRetrospective Studiesgamma-GlutamyltransferaseCovid-19critically ill patientsliverlung transplantationsecondary sclerosing cholangitis

Identifiers

PMID35907758
PMCPMC9249665
OpenAlexW4283778282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.